Nyxoah SA Ordinary Shares
NYXHStock
$1.62−78.38%52W
Market Cap$162.69M
P/E—
Div yield—
Beta1.14
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-75.97%
Price vs S&P 500 (4W)3.06%
VGM Score45.45
Market Capitalization$162.69M
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.07
4.07
4.07
4.07
Industry Peers — Surgical & Medical Instruments(141)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
NYXHNyxoah SA Ordinary Shares | D | A | F | $1.62 |
| SYKStryker Corporation | C | C | D | $331.20 |
| MMM3M Company | C | F | B | $161.77 |
| BSXBoston Scientific Corp. | C | B | F | $44.62 |
| MDLNMedline Inc. Class A common stock | C | D | D | $41.11 |
| BDXBecton, Dickinson and Co. | B | C | B | $159.93 |
| DXCMDexCom, Inc. | C | B | C | $77.98 |
| RMDResMed Inc. | C | B | D | $202.76 |
| WSTWest Pharmaceutical Services, Inc. | D | C | A | $362.44 |
| SOLVSolventum Corporation | C | D | B | $81.70 |
| PENPenumbra, Inc. | F | C | B | $319.60 |
About
Nyxoah SA develops and commercializes the Genio system, a CE-Mark validated bilateral neurostimulation therapy for moderate to severe Obstructive Sleep Apnea (OSA). The company addresses a substantial patient population, as OSA is associated with increased mortality risk and serious comorbidities including cardiovascular disease, depression, and stroke. Genio represents a novel treatment approach in a significant market opportunity for sleep-disordered breathing.